First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), J Clin Oncol, 23
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors.
Plummer R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 208S - 208S
Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV).
Midgley R. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 213S - 213S
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), J Clin Oncol, 23
The use of pharmacokinetic and pharmacodynamic endpoints to determine dose of AQ4N given with radiotherapy (RT).
Benghiat A. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 150S - 150S
Drugging cell cycle kinases in cancer therapy.
Blagden S. and de Bono J., (2005), Curr Drug Targets, 6, 325 - 335
Docetaxel in the management of ovarian cancer.
Blagden SP. and Kaye SB., (2005), Expert Rev Anticancer Ther, 5, 203 - 214
Optimising the use of arsenic trioxide in 'high risk' acute promyelocytic leukaemia (APL): The UK experience
Grimwade D. et al, (2005), BRITISH JOURNAL OF HAEMATOLOGY, 129, 28 - 28
Preliminary experience using extracorporeal high-intensity focused ultrasound for the treatment of kidney and liver tumours
Illing RO. et al, (2005), AIP Conference Proceedings, 754, 13 - 16
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling.
Payne MJ. et al, (2005), Crit Rev Oncol Hematol, 53, 241 - 252
Temozolomide in the treatment of solid tumours: current results and rationale for dosing/scheduling
Payne MJ. et al, (2005), CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 53, 241 - 252
A phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of the histone deacetylase (HDAC) inhibitor PXD101 in patients (pts) with advanced solid tumours.
Steele N. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 200S - 200S
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.
Pacey S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 205S - 205S
Phase I study of intravenous TZT-1027 (T) and carboplatin (C), administered on Day 1 (T and C) and Day 8 (T) every three weeks in patients (pts) with advanced solid tumors
Blagden S. et al, (2005), JOURNAL OF CLINICAL ONCOLOGY, 23, 226S - 226S
Phase I study of ispinesib (SB-715992) in combination with docetaxel in patients with advanced solid tumors.
Blagden S. et al, (2005), CLINICAL CANCER RESEARCH, 11, 9119S - 9119S
Temozolomide Pharmacodynamics in Patients with Metastatic Melanoma: DNA Damage and Activity of Repair Enzymes O6-Alkylguanine Alkyltransferase and Poly(ADP-Ribose) Polymerase-1
Plummer ER. et al, (2005), Clin Cancer Res, 11, 3402 - 3409
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), JOURNAL OF CLINICAL ONCOLOGY, 22, 149S - 149S
Phase 1 dose escalation study of AQ4N, a selective hypoxic cell cytotoxin, with fractionated radiotherapy (RT): First report.
Benghiat A. et al, (2004), J Clin Oncol, 22